Following #ENA2026 in Barcelona, Erasca will host a virtual investor event on November 20 at 8:00 a.m. ET, highlighting clinical momentum across our RAS-targeting franchise. To register and learn more, visit: bit.ly/4iMRfqk
2
210
Tomorrow is National Lung Cancer Screening Day. At Erasca, we support screening and early detection awareness as we advance ERAS-0015, an investigational therapy for RAS-mutant cancers. Learn more: nlcrt.org/whats-happening/lu…
#LCSDay2026 #LCAM
1
60
Check out our Q3 2026 results and corporate updates, which highlight continued momentum across our pipeline as we advance toward our goal of developing treatments for #pancreatic and #lung cancers. More: bit.ly/4sXSkAx
1
54
Erasca has won the @BioTech_Awards 2026 R&D Platform of the Year award! Thank you to our team, researchers, clinicians, patients and partners for helping advance our mission to erase cancer
Learn more about our work: bit.ly/4BF5oii
2
95
This November, Erasca’s management team will attend @GuggenheimSec, @Stifel, and @Jefferies #healthcare conferences to meet with investors and share progress in advancing therapies for RAS/MAPK-driven #cancers.
More here: bit.ly/4A9A6OT
November is #LungCancerAwarenessMonth and #PancreaticCancerAwarenessMonth. We’re advancing new therapies for RAS/MAPK-driven cancers, including lung and pancreatic cancers, toward our mission of erasing cancer. Learn more: bit.ly/4BF5oii
56
Little Erascals, BIG Halloween spirit! 🎃 Our team and their families celebrated with costumes, trick-or-treating, snacks, and crafts. Here’s a peek at the fun! #TeamErasca #HappyHalloween
1
2
131
Thank you, @LustgartenFDN, for the Hope Through Science Award. We’re proud to support the shared mission of improving outcomes for patients with pancreatic cancer. #PancreaticCancer
RAS mutations drive ~30% of all cancers. Thank you, @stephaniesirota, for the opportunity to discuss Erasca’s journey and our commitment to advancing therapies for patients with RAS/MAPK-driven cancers. #ASCO2026
In our #ASCO2026 coffee break miniseries, RTW CBO @stephaniesirota chatted with Dr. Shannon Morris, Chief Medical Officer of @Erasca. Dr. Morris shared the story behind Erasca's name and what it took to pursue a corner of oncology that was historically considered undruggable. The mic drop moment is when Dr. Morris shares that RAS mutations drive 30% of all tumor types.
223
Erasca retweeted
We’re proud to join Erasca in a strategic research and development collaboration to evaluate multiple agents from their pipeline targeting the RAS/MAPK pathway.
Learn more: fal.cn/3rgJV @Erasca @SKopetz @DavidHongMD #EndCancer
Erasca retweeted
Please join us for the @Erasca Virtual R&D Day on Lead Clinical Programs ERAS-007 & ERAS-601 in Advanced Solid Tumors featuring Dr. David Hong (MD Anderson Cancer Center). A live Q&A session will follow. Register Here: lifesci.events/ERAS2
Please join us for this exciting event!
Please join us on Tuesday, April 12th at 4:30 PM EDT for the @Erasca Investor Event featuring Scott Kopetz, M.D., Ph.D., (MD Anderson Cancer Center). A live Q&A session will follow. Register here: lifesci.events/ERAS
Erasca retweeted
A big, warm welcome to the @erascainc team! 👏👏👏
Erasca, Inc. joins us in Times Square to ring the @Nasdaq Opening Bell in honor of their IPO. 🎉 #EraseCancer
Erasca retweeted
Welcome to the @Nasdaq family, @erascainc!
Erasca, Inc. is a clinical-stage precision oncology company driven by a bold mission: to erase cancer by shutting down one of cancer's most commonly mutated pathways. #EraseCancer
Now trading: $ERAS
Erasca retweeted
.@erascainc is a clinical-stage precision oncology company driven by a bold mission—to erase cancer. We speak with CEO Jonathan E. Lim, M.D., about the company’s vision. nitter.cf/i/broadcasts/1YqGoypaX…

























